Description

Adults and adolescents aged 13 years and over:

– Monotherapy or combination treatment for partial and generalized epilepsy, including tonic-clonic seizures.

– Seizures associated with Lennox-Gastaut syndrome. Lamilep is administered in combination with another treatment but may be the first-line anti-epileptic drug (AE) in Lennox-Gastaut syndrome.

Children and adolescents aged 2 to 12 years:

– Combination treatment for partial and generalized epilepsy, including tonic-clonic seizures and seizures associated with Lennox-Gastaut syndrome.

– Monotherapy treatment for typical absences.

Bipolar Disorders Adults aged 18 years and older:

– Prevention of depressive episodes in patients with bipolar I disorder who have a predominance of depressive episodes Lamilep is not indicated for the acute treatment of manic or depressive episodes.